Request Free Sample ×
US Varicose Veins Treatment Market Research Report- Forecast to 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Varicose Veins Treatment Market

ID: MRFR/Pharma/15202-HCR
100 Pages
Satyendra Maurya
Last Updated: April 06, 2026

United States Varicose Veins Treatment Market Research Report: Size, Share, Trend Analysis - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Varicose Veins Treatment Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Chemicals and Materials, BY Treatment Type (USD Million)
  49.     4.1.1 Sclerotherapy
  50.     4.1.2 Laser Therapy
  51.     4.1.3 Endovenous Laser Treatment
  52.     4.1.4 Radiofrequency Ablation
  53.     4.1.5 Surgical Ligation
  54.   4.2 Chemicals and Materials, BY Procedure Type (USD Million)
  55.     4.2.1 Minimally Invasive
  56.     4.2.2 Surgical
  57.     4.2.3 Ambulatory
  58.   4.3 Chemicals and Materials, BY End User (USD Million)
  59.     4.3.1 Hospitals
  60.     4.3.2 Ambulatory Surgical Centers
  61.     4.3.3 Specialty Clinics
  62.     4.3.4 Home Healthcare
  63.   4.4 Chemicals and Materials, BY Age Group (USD Million)
  64.     4.4.1 Adults
  65.     4.4.2 Elderly
  66.     4.4.3 Pediatric
  67. 5 SECTION V: COMPETITIVE ANALYSIS
  68.   5.1 Competitive Landscape
  69.     5.1.1 Overview
  70.     5.1.2 Competitive Analysis
  71.     5.1.3 Market share Analysis
  72.     5.1.4 Major Growth Strategy in the Chemicals and Materials
  73.     5.1.5 Competitive Benchmarking
  74.     5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  75.     5.1.7 Key developments and growth strategies
  76.       5.1.7.1 New Product Launch/Service Deployment
  77.       5.1.7.2 Merger & Acquisitions
  78.       5.1.7.3 Joint Ventures
  79.     5.1.8 Major Players Financial Matrix
  80.       5.1.8.1 Sales and Operating Income
  81.       5.1.8.2 Major Players R&D Expenditure. 2023
  82.   5.2 Company Profiles
  83.     5.2.1 Medtronic (US)
  84.       5.2.1.1 Financial Overview
  85.       5.2.1.2 Products Offered
  86.       5.2.1.3 Key Developments
  87.       5.2.1.4 SWOT Analysis
  88.       5.2.1.5 Key Strategies
  89.     5.2.2 Boston Scientific (US)
  90.       5.2.2.1 Financial Overview
  91.       5.2.2.2 Products Offered
  92.       5.2.2.3 Key Developments
  93.       5.2.2.4 SWOT Analysis
  94.       5.2.2.5 Key Strategies
  95.     5.2.3 Abbott Laboratories (US)
  96.       5.2.3.1 Financial Overview
  97.       5.2.3.2 Products Offered
  98.       5.2.3.3 Key Developments
  99.       5.2.3.4 SWOT Analysis
  100.       5.2.3.5 Key Strategies
  101.     5.2.4 B. Braun Melsungen AG (DE)
  102.       5.2.4.1 Financial Overview
  103.       5.2.4.2 Products Offered
  104.       5.2.4.3 Key Developments
  105.       5.2.4.4 SWOT Analysis
  106.       5.2.4.5 Key Strategies
  107.     5.2.5 Cook Medical (US)
  108.       5.2.5.1 Financial Overview
  109.       5.2.5.2 Products Offered
  110.       5.2.5.3 Key Developments
  111.       5.2.5.4 SWOT Analysis
  112.       5.2.5.5 Key Strategies
  113.     5.2.6 Teleflex Incorporated (US)
  114.       5.2.6.1 Financial Overview
  115.       5.2.6.2 Products Offered
  116.       5.2.6.3 Key Developments
  117.       5.2.6.4 SWOT Analysis
  118.       5.2.6.5 Key Strategies
  119.     5.2.7 Stryker Corporation (US)
  120.       5.2.7.1 Financial Overview
  121.       5.2.7.2 Products Offered
  122.       5.2.7.3 Key Developments
  123.       5.2.7.4 SWOT Analysis
  124.       5.2.7.5 Key Strategies
  125.     5.2.8 AngioDynamics (US)
  126.       5.2.8.1 Financial Overview
  127.       5.2.8.2 Products Offered
  128.       5.2.8.3 Key Developments
  129.       5.2.8.4 SWOT Analysis
  130.       5.2.8.5 Key Strategies
  131.   5.3 Appendix
  132.     5.3.1 References
  133.     5.3.2 Related Reports
  134. 6 LIST OF FIGURES
  135.   6.1 MARKET SYNOPSIS
  136.   6.2 US MARKET ANALYSIS BY TREATMENT TYPE
  137.   6.3 US MARKET ANALYSIS BY PROCEDURE TYPE
  138.   6.4 US MARKET ANALYSIS BY END USER
  139.   6.5 US MARKET ANALYSIS BY AGE GROUP
  140.   6.6 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
  141.   6.7 RESEARCH PROCESS OF MRFR
  142.   6.8 DRO ANALYSIS OF CHEMICALS AND MATERIALS
  143.   6.9 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
  144.   6.10 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
  145.   6.11 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
  146.   6.12 CHEMICALS AND MATERIALS, BY TREATMENT TYPE, 2024 (% SHARE)
  147.   6.13 CHEMICALS AND MATERIALS, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
  148.   6.14 CHEMICALS AND MATERIALS, BY PROCEDURE TYPE, 2024 (% SHARE)
  149.   6.15 CHEMICALS AND MATERIALS, BY PROCEDURE TYPE, 2024 TO 2035 (USD Million)
  150.   6.16 CHEMICALS AND MATERIALS, BY END USER, 2024 (% SHARE)
  151.   6.17 CHEMICALS AND MATERIALS, BY END USER, 2024 TO 2035 (USD Million)
  152.   6.18 CHEMICALS AND MATERIALS, BY AGE GROUP, 2024 (% SHARE)
  153.   6.19 CHEMICALS AND MATERIALS, BY AGE GROUP, 2024 TO 2035 (USD Million)
  154.   6.20 BENCHMARKING OF MAJOR COMPETITORS
  155. 7 LIST OF TABLES
  156.   7.1 LIST OF ASSUMPTIONS
  157.     7.1.1
  158.   7.2 US MARKET SIZE ESTIMATES; FORECAST
  159.     7.2.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  160.     7.2.2 BY PROCEDURE TYPE, 2025-2035 (USD Million)
  161.     7.2.3 BY END USER, 2025-2035 (USD Million)
  162.     7.2.4 BY AGE GROUP, 2025-2035 (USD Million)
  163.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  164.     7.3.1
  165.   7.4 ACQUISITION/PARTNERSHIP
  166.     7.4.1

US Chemicals and Materials Market Segmentation

Chemicals and Materials By Treatment Type (USD Million, 2025-2035)

  • Sclerotherapy
  • Laser Therapy
  • Endovenous Laser Treatment
  • Radiofrequency Ablation
  • Surgical Ligation

Chemicals and Materials By Procedure Type (USD Million, 2025-2035)

  • Minimally Invasive
  • Surgical
  • Ambulatory

Chemicals and Materials By End User (USD Million, 2025-2035)

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics
  • Home Healthcare

Chemicals and Materials By Age Group (USD Million, 2025-2035)

  • Adults
  • Elderly
  • Pediatric

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓